Chemistry:Dapirolizumab pegol
From HandWiki
| Identifiers | |
|---|---|
| CAS Number | |
| DrugBank | |
| UNII | |
Dapirolizumab pegol is "a polyethylene glycol conjugated anti-CD40L Fab fragment" developed by Biogen for systemic lupus erythematosus.[1][2][3]
References
- ↑ Chamberlain, Chris; Colman, Peter J; Ranger, Ann M; Burkly, Linda C; Johnston, Geoffrey I; Otoul, Christian; Stach, Christian; Zamacona, Miren et al. (November 2017). "Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles". Annals of the Rheumatic Diseases 76 (11): 1837–1844. doi:10.1136/annrheumdis-2017-211388. PMID 28780512.
- ↑ Askanase, A.; Stach, C.; Brittain, C.; Stojan, G.; Furie, R. (1 June 2023). "Pos0115 Dapirolizumab Pegol Efficacy by Subgroups in Patients with Systemic Lupus Erythematosus: A Post Hoc Analysis of Phase 2 Clinical Trial Data" (in en). Annals of the Rheumatic Diseases 82 (Suppl 1): 272–273. doi:10.1136/annrheumdis-2023-eular.1991. ISSN 0003-4967. https://ard.bmj.com/content/82/Suppl_1/272.1.
- ↑ Furie, Richard A; Bruce, Ian N; Dörner, Thomas; Leon, Manuel Gustavo; Leszczyński, Piotr; Urowitz, Murray; Haier, Birgit; Jimenez, Teri et al. (6 May 2021). "Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol inpatients with moderate-to-severe active systemic lupus erythematosus". Rheumatology 60 (11): 5397–5407. doi:10.1093/rheumatology/keab381. ISSN 1462-0324. PMID 33956056.
 |  |
